AFP and acute myeloid leukemia: Median OS was superimposable in patients who did and did not receive AFP (8.1 months vs. 12.5 months);Poor fitness (HR 4.21) and TP53 mutation (HR 3.06);No significant differences in IFD’s incidence, OS, proportion of patients proceeding to HCT or experiencing relapse according to AFP use.Concurrent VEN dose reduction did not compromise AML outcomes.